CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer

Gynecologic Oncology

Volumn 121, Issue 2, 2011, Pages 249-252

  Fleming, Nicole D ^a   Cass, Ilana ^a   Walsh, Christine S ^a   Karlan, Beth Y ^a   Li, Andrew J ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

CA125; Secondary cytoreduction

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; ASCITES; CANCER RECURRENCE; CANCER SURGERY; CARCINOMATOSIS; CYTOREDUCTIVE SURGERY; EPITHELIAL OVARIAN CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 79955447888     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.01.014     Document Type: Article

References (18)

1. R.E. Bristow, R.S. Tomacruz, D.K. Armstrong, E.L. Trimble, and F.J. Montz Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis J Clin Oncol 20 2002 1248 1259 (Pubitemid 34177431)
2. R.E. Bristow, I. Puri, and D.S. Chi Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis Gynecol Oncol 112 2009 265 274
3. R.C. Bast Jr. CA125 and the detection of recurrent ovarian cancer Cancer 116 12 2010 2850 2853
4. G.J. Rustin, A.E. Nelstrop, M.K. Tuxen, and H.E. Lambert Defining progression of ovarian carcinoma during follow-up according to CA125: a North Thames Ovary Group Study Ann Oncol 7 1996 361 364 (Pubitemid 26246787)
5. G.J. Rustin, M. Marples, A.E. Nelstrop, M. Mahmoudi, and T. Meyer Use of CA125 to define progression of ovarian cancer in patients with persistently elevated levels J Clin Oncol 19 2001 4054 4057 (Pubitemid 32976692)
6. L.J. Havrilesky, C.M. Whitehead, and J.M. Rubatt Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence Gynecol Oncol 110 2008 374 382
7. G.J. Rustin, M.E. van der Burg, and C.L. Griffin Early versus delayed treatment of relapsed ovarian cancer (MRC OV5/EORTC 55955): a randomized trial Lancet 376 2010 1155 1163
8. A. Gadducci, P. Iacconi, and S. Cosio Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer Gynecol Oncol 79 2000 344 349
9. S.M. Eisenkop, R.L. Friedman, and N.M. Spirtos The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma Cancer 88 2000 144 153 (Pubitemid 30027690)
10. A.R. Munkarah, and R.L. Coleman Critical evaluation of secondary cytoreduction in recurrent ovarian cancer Gynecol Oncol 95 2004 273 280 (Pubitemid 39445861)
11. R.Y. Zang, Z.T. Li, and X. Cheng Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer 100 2004 1152 1161 (Pubitemid 38325942)
12. D.S. Chi, K. McCaughty, and J.P. Diaz Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma Cancer 106 2006 1933 1939 (Pubitemid 43673208)
13. P. Harter, A. du Bois, and A. Hahmann Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial Ann Surg Oncol 13 2006 1702 1710 (Pubitemid 44951480)
14. R. Salani, A. Santillan, and M.L. Zahurak Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome Cancer 109 2007 685 691 (Pubitemid 46233229)
15. P. Benedetti Panici, A. De Vivo, and F. Bellati Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer Ann Surg Oncol 14 2007 1136 1142
16. R.E. Bristow, I. Puri, and D.S. Chi Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis Gynecol Oncol 112 2009 265 274
17. A. Santillan, R. Garg, and M.L. Zahurak Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range J Clin Oncol 23 2005 9338 9343
18. P.A. Parker, A. Kudelka, and K. Basen-Engquist The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer Gynecol Oncol 100 3 2006 495 500 (Pubitemid 43246864)